[Molecular pathogenesis. Its importance in targeted therapy in colorectal cancer].
Colorectal cancer has the second highest mortality of all cancers in Germany. In spite of advances in surgical and chemotherapeutic treatment, efficient new therapies need to be developed. In recent years, advances have been achieved by novel targeted therapies that are specifically directed against altered signaling pathways of malignant cells. Colorectal cancers represent a heterogeneous tumor entity, and response to targeted therapies varies individually. About 15% of colorectal carcinomas are characterized by a deficient DNA mismatch repair system and microsatellite instability (MSI). These MSI cancers apparently have a decreased sensitivity to chemotherapy and frequently show evidence of a pronounced anti-tumoral immune response of the host. This immune response is likely to be mediated by a high number of tumor-specific antigens generated during MSI tumorigenesis. Interventions specifically targeting these antigens may be the basis for novel therapeutic strategies in MSI colorectal cancer and will be evaluated in clinical trials.
Kloor
M
M
Abteilung für Angewandte Tumorbiologie, Institut für Pathologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 220, 69120 Heidelberg. matthias.kloor@med.uni-heidelberg.de
Michel
S
S
von Knebel Doeberitz
M
M
D000951:Antigens, Neoplasm / Q000276:immunology; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D053843:DNA Mismatch Repair / Q000235:genetics; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy; D053842:Microsatellite Instability; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D052416:Targeted Gene Repair
D000951:Antigens, Neoplasm